Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.
about
Molecular recognition of CCR5 by an HIV-1 gp120 V3 loopCCR5 monoclonal antibodies for HIV-1 therapyA putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency virusesTyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.Atomic-level mapping of antibody epitopes on a GPCRNovel approaches to inhibit HIV entryThe regulation of inflammatory pathways and infectious disease of the cervix by seminal fluidHIV and the chemokine system: 10 years later.Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptorAllosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityEffects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors.The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1.Identification of CXCR4 domains that support coreceptor and chemokine receptor functionsFunctional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strainsDifferential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageMultiple residues contribute to the inability of murine CCR-5 to function as a coreceptor for macrophage-tropic human immunodeficiency virus type 1 isolates.Chemokine receptor utilization by human immunodeficiency virus type 1 isolates that replicate in microglia.Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.Antigenically distinct conformations of CXCR4.CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsDistinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses.An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.
P2860
Q21559473-94DD60E2-7998-4021-BC5C-7024269E88ECQ22242739-F722BFD6-54F7-4B44-85A2-3E41139351B0Q24524308-9713BB33-74ED-4BDC-B3B9-F3705A2C22BEQ24534959-35369701-3DF1-4890-87FB-3EDD4D708110Q24604442-3027C942-0593-48EC-88B0-8F003520FCD3Q27013957-16A926F9-84D1-405F-9E25-17AC7C0CF55CQ27024447-B5F602F8-7D8D-4326-94C9-C974E8647978Q27473020-DD79FE2D-1DAF-4F9C-B5F5-003989083F88Q27643185-8B3B60C8-F27D-4992-9EE4-37C11D308F90Q27648643-355B6B0E-6EE7-4389-A603-2448910B25A0Q28344177-1E72BA71-45BC-4C7E-9A63-2B06BAEC402BQ28344310-2D5D2804-9517-45E3-9296-87457A1D6C35Q28379187-2E5740CC-92A1-4BC5-84F5-209FE2713346Q28485983-8C2A378C-1567-4F50-8BD9-03EED2247ABFQ29622903-988431AD-A5B4-4D27-811E-742923E66DB0Q33377026-60DF20F8-17E0-444B-BDB2-96307233A69EQ33595068-C79D8881-BA97-4DEE-A59B-0C992F490740Q33643223-DDF94280-A9EF-42D6-A173-CB5C0DC599D9Q33647409-DA5D607B-591D-4801-85DD-7C02C1E1E3AFQ33647608-2974B7BE-DCD6-4B47-95D7-5470CE31F5C3Q33782007-EB816ED1-F33F-4E0A-BCB7-DC8206C44871Q33782296-C1F55DE0-1892-46F2-9E28-887433EB6218Q33782312-85AAFEEF-E30B-40ED-A7A2-653421D1016DQ33782833-7756B109-0A51-4394-811F-2215CB30D040Q33783914-19614114-51D5-497A-83CB-800AF2253234Q33797534-F82F1AB8-9264-4C4C-94D4-4829A7C87EB2Q33804016-542D9E3C-7588-43CB-8E32-A94BB4460E25Q33813025-F9505674-F787-4706-957E-A3D3D93D9CE0Q33841935-E2FAEC3D-546F-4194-BF9B-C028C1B0C193Q33845055-7F78751C-B3CD-4DC0-9CA0-E9EBD332C381Q33848876-A2D13BA8-5AD4-4E8A-9489-12853C3B6779Q33851094-FFD21D9A-2228-4D18-8F18-018EC8A61278Q33857491-846EE29E-1E10-4B38-AF3F-32EE192E06E3Q33890786-AEA707B4-08CF-41E6-9D90-39CE630138BFQ33990552-C7F5BECA-0A14-436C-89EF-A4643AEAB8EDQ34055508-E30C1338-BDD8-4DC1-8AF4-AB6F44992ED3Q34610959-B5759E4A-2E12-4460-9721-42EFD6280CFFQ34744722-64EEBB3E-AE66-490A-9F1D-B5AB457EACF1Q34979722-6BB91995-0A10-45BD-AA5A-9051665EF808Q34987062-8F5BB797-7679-4C67-B18B-E64CA6BF75B1
P2860
Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Two distinct CCR5 domains can ...... immunodeficiency virus type 1.
@ast
Two distinct CCR5 domains can ...... immunodeficiency virus type 1.
@en
type
label
Two distinct CCR5 domains can ...... immunodeficiency virus type 1.
@ast
Two distinct CCR5 domains can ...... immunodeficiency virus type 1.
@en
prefLabel
Two distinct CCR5 domains can ...... immunodeficiency virus type 1.
@ast
Two distinct CCR5 domains can ...... immunodeficiency virus type 1.
@en
P2093
P2860
P1433
P1476
Two distinct CCR5 domains can ...... immunodeficiency virus type 1
@en
P2093
B J Doranz
M A Accavitti
S C Peiper
P2860
P304
P407
P577
1997-09-01T00:00:00Z